Phase I trial

SUZHOU, China, May 6, 2026 SiranBio announced a major global licensing agreement with GSK for its investigational siRNA therapeutic...

STOCKHOLM, Sweden – May 6, 2026 Spago Nanomedical AB (publ) has announced that its ongoing Phase I/IIa Tumorad-01 study...

SHANGHAI, April 10, 2026 Shanghai Ark Biopharmaceutical Co., Ltd. has announced a key clinical milestone with the successful dosing...

Cambridge, Massachusetts, USA / Rotterdam, Netherlands / Shanghai, China | March 22, 2026 Harbour BioMed has announced the online...